These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 23685026

  • 1. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G, Siakantaris M, Papadaki T, Papadavid E, Vassilakopoulos TP, Angelopoulou MK, Marinos L, Nikolaou V, Economidi A, Antoniou C, Patsouris E, Korkolopoulou P.
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [Abstract] [Full Text] [Related]

  • 2. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka EA, Sakellariou S, Kavantzas N, Patsouris E, Saetta AA.
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [Abstract] [Full Text] [Related]

  • 3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S, Nakahara T, Uchi H, Takeuchi S, Takahara M, Kido M, Dugu L, Tu Y, Moroi Y, Furue M.
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N, Kohashi K, Fushimi F, Endo M, Yamamoto H, Takahashi Y, Yamada Y, Ishii T, Yokoyama K, Iwamoto Y, Oda Y.
    Cancer; 2013 Oct 01; 119(19):3504-13. PubMed ID: 23861137
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE, Sakellariou S, Levidou G, Theodorou D, Michalopoulos NV, Patsouris E, Korkolopoulou P, Saetta AA.
    APMIS; 2015 Aug 01; 123(8):639-47. PubMed ID: 25912437
    [Abstract] [Full Text] [Related]

  • 7. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.
    Clin Cancer Res; 2004 Sep 01; 10(17):5820-7. PubMed ID: 15355912
    [Abstract] [Full Text] [Related]

  • 8. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.
    Clin Cancer Res; 2004 Oct 15; 10(20):6779-88. PubMed ID: 15501954
    [Abstract] [Full Text] [Related]

  • 9. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y, Kohashi K, Fushimi F, Takahashi Y, Setsu N, Endo M, Yamamoto H, Tokunaga S, Iwamoto Y, Oda Y.
    Cancer; 2014 Mar 15; 120(6):864-76. PubMed ID: 24353015
    [Abstract] [Full Text] [Related]

  • 10. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.
    Am J Pathol; 2006 Dec 15; 169(6):2171-80. PubMed ID: 17148679
    [Abstract] [Full Text] [Related]

  • 11. Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.
    Lakiotaki E, Levidou G, Angelopoulou MK, Adamopoulos C, Pangalis G, Rassidakis G, Vassilakopoulos T, Gainaru G, Flevari P, Sachanas S, Saetta AA, Sepsa A, Moschogiannis M, Kalpadakis C, Tsesmetzis N, Milionis V, Chatziandreou I, Thymara I, Panayiotidis P, Dimopoulou M, Plata E, Konstantopoulos K, Patsouris E, Piperi C, Korkolopoulou P.
    Sci Rep; 2016 Feb 19; 6():21252. PubMed ID: 26893254
    [Abstract] [Full Text] [Related]

  • 12. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
    Li JF, Li GD, Gu L, Liu WP, Li FY, Liao DY, Ma ZG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct 19; 29(10):649-53. PubMed ID: 19176054
    [Abstract] [Full Text] [Related]

  • 13. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
    Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A.
    Hum Pathol; 2011 Feb 19; 42(2):214-26. PubMed ID: 21040950
    [Abstract] [Full Text] [Related]

  • 14. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S.
    Cancer; 2006 Oct 15; 107(8):1801-11. PubMed ID: 16983702
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
    Iwasaki T, Matsushita M, Nonaka D, Kuwamoto S, Kato M, Murakami I, Nagata K, Nakajima H, Sano S, Hayashi K.
    Hum Pathol; 2015 Feb 15; 46(2):210-6. PubMed ID: 25466966
    [Abstract] [Full Text] [Related]

  • 16. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct 15; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 17. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
    Liontos M, Trigka EA, Korkolopoulou P, Tzannis K, Lainakis G, Koutsoukos K, Kostouros E, Lykka M, Papandreou CN, Karavasilis V, Christodoulou C, Papatsoris A, Skolarikos A, Varkarakis I, Adamakis I, Alamanis C, Stravodimos K, Mitropoulos D, Deliveliotis C, Constantinidis CA, Saetta A, Patsouris E, Dimopoulos MΑ, Bamias A.
    World J Urol; 2017 Mar 15; 35(3):411-419. PubMed ID: 27395374
    [Abstract] [Full Text] [Related]

  • 18. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.
    Oncol Rep; 2013 Aug 15; 30(2):623-36. PubMed ID: 23728071
    [Abstract] [Full Text] [Related]

  • 19. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD, Nien WL, Dauphinee SM, Too CK.
    J Endocrinol; 2006 Aug 15; 190(2):307-12. PubMed ID: 16899564
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.
    Clin Cancer Res; 2013 Jan 15; 19(2):450-61. PubMed ID: 23209032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.